protection planning, historic preservation, and natural resource protection.

Commission meetings consist of the following:

1. General Introductions
2. Park Operations Briefing
3. Reports and Discussions
4. Old Business
5. New Business
6. Public Comments
7. Closing Remarks

*Meeting Accessibility/Special Accommodations:* The meeting is open to the public. Please make requests in advance for sign language interpreter services, assistive listening devices, or other reasonable accommodations. We ask that you contact the person listed in the **FOR FURTHER INFORMATION CONTACT** section of this notice at least seven (7) business days prior to the meeting to give the Department of the Interior sufficient time to process your request. All reasonable accommodation requests are managed on a case-by-case basis.

*Public Disclosure of Comments:* Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public view, we cannot guarantee that we will be able to do so.

(Authority: 5 U.S.C. Ch. 10.)

**Alma Ripps,**

*Chief, Office of Policy.*

[FR Doc. 2026–18250 Filed 9–4–26; 8:45 am]

**BILLING CODE 4312–52–P**

## INTERNATIONAL TRADE COMMISSION

**[Investigation No. 337–TA–1443]**

## Certain Foreign-Fabricated Semiconductor Devices, Products Containing the Same, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Granting a Joint Motion To Terminate the Investigation

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (''ID'') (Order No. 77) of the presiding administrative law judge (''ALJ'') granting a joint motion to terminate the investigation in its entirety based on settlement and to limit service of the settlement agreement.

**FOR FURTHER INFORMATION CONTACT:** Lisa A. Murray, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2781. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205–1810.

**SUPPLEMENTARY INFORMATION:** On March 26, 2025, the Commission instituted the present investigation based on a complaint, as supplemented, filed by Longitude Licensing Ltd. and Marlin Semiconductor Limited, both of Dublin, Ireland (''Complainants''). 90 FR 13779–81 (Mar. 26, 2025). The complaint alleged violations of section 337 of Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain foreign-fabricated semiconductor devices, products containing the same, and components thereof, that infringe one or more of the asserted claims of U.S. Patent Nos. 7,745,847 (''the '847 patent''); 9,093,473 (''the '473 patent''); 9,147,747 (''the '747 patent''); 9,184,292 (''the '292 patent''); and 9,953,880 (''the '880 patent''). *Id.* The complaint also alleges that a domestic industry exists or is in the process of being established. *Id.*

The notice of investigation names the following respondents: Taiwan Semiconductor Manufacturing Company Limited of Hsinchu, Taiwan; Apple of Cupertino, California; Broadcom Inc. of Palo Alto, California; Lenovo Group Limited (''LGL'') of Hong Kong S.A.R., China; Motorola (Wuhan) Mobility Technologies, Communication Company Limited of Wuhan, China; Motorola Mobile Communication, Technology Ltd. of Xiamen, China; OnePlus Technology (Shenzhen) Co., Ltd. of Shenzhen, China; and Qualcomm Inc. of San Diego, California. The Office of Unfair Import Investigations (''OUII'') has also been named as a party to this investigation.

On August 14, 2025, the Commission amended the complaint and notice of investigation to terminate respondent LGL and substitute LGL with respondents: Lenovo (Shanghai) Electronics Technology Co., Ltd. of Shanghai, China; Lenovo PC International Ltd.; Lenovo PC HK Ltd. of Quarry Bay, Hong Kong; Lenovo Information Products (Shenzhen) Co., Ltd. of Shenzhen, China; Lenovo Beijing Co., Ltd. of Beijing, China; and Lenovo (United States) Inc. of Morrisville, North Carolina. *See* Order No. 34 (July 21, 2025), *unreviewed by* Comm'n Notice (Aug. 14, 2025); 90 FR 40398 (Aug. 19, 2025).

The Commission previously terminated the investigation as to claims 1–5 and 7–11 of the '847 patent; claims 3–10 of the '473 patent; claims 1–3 and 6–7 of the '747 patent; claims 1, 5–9, 11–15, and 17–20 of the '292 patent; and claims 1–12 of the '880 patent, based on withdrawal of the complaint as to those claims. *See* Order No. 36 (July 31, 2025), *unreviewed by* Comm'n Notice (Aug. 14, 2025); Order No. 47 (Nov. 19, 2025), *unreviewed by* Comm'n Notice (Dec. 15, 2025); Order No. 52 (Dec. 31, 2025), *unreviewed by* Comm'n Notice (Jan. 15, 2026); Order No. 66 (Jan. 30, 2026), *unreviewed by* Comm'n Notice (Feb. 24, 2026).

On June 26, 2026, the Commission terminated the investigation as to Apple on the basis of a settlement agreement. Order No. 71 (June 16, 2026), *unreviewed by* Comm'n Notice (June 26, 2026).

On July 14, 2026, Complainants and respondent Taiwan Semiconductor Manufacturing Company Limited (''TSMC'') filed an unopposed joint motion to terminate the investigation based upon settlement. On July 21, 2026, OUII filed a response supporting the motion.

On August 5, 2026, the ALJ issued the subject ID (Order No. 77) pursuant to Commission Rule 210.21(b), 19 CFR 210.21(b), granting the joint motion to terminate the investigation. The ID finds that the joint motion complies with Commission Rule 210.21(b). Pursuant to Commission Rule 210.21(b)(1), 19 CFR 210.21(b)(1), the ALJ also found that good cause exists to limit service of the unredacted Confidential Settlement Agreements attached to the joint motion to Complainant, TSMC, and OUII. Because all remaining Respondents in this investigation are alleged direct or indirect customers of TSMC, the ID terminates the investigation in its entirety. No petitions for review of the ID were filed.

The Commission has determined not to review the ID. The investigation is terminated in its entirety.

The Commission vote for this determination took place on September 3, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: September 3, 2026.

**Lisa R. Barton,**

*Secretary to the Commission.*

[FR Doc. 2026–18260 Filed 9–4–26; 8:45 am]

**BILLING CODE 7020–02–P**

## INTERNATIONAL TRADE COMMISSION

**[Investigation Nos. 701–TA–767 and 731–TA–1750 (Final)]**

### L-Lysine From China

### Determinations

On the basis of the record [1] developed in the subject investigations, the United States International Trade Commission (''Commission'') determines, pursuant to the Tariff Act of 1930 (''the Act''), that an industry in the United States is materially injured by reason of imports of L-lysine (''lysine'') from China, provided for in subheading 2922.41.00 of the Harmonized Tariff Schedule of the United States, that have been found by the U.S. Department of Commerce (''Commerce'') to be sold in the United States at less than fair value (''LTFV''), and imports of the subject merchandise from China that have been found to be subsidized by the government of China.[2] [3]

### Background

The Commission instituted these investigations effective May 28, 2025, following receipt of petitions filed with the Commission and Commerce by Archer Daniels Midland Company (''ADM''), Chicago, Illinois; CJ Bio America, Inc., an Iowa Corporation (''CJ Bio''), Fort Dodge, Iowa; and Evonik Corporation (''Evonik''), Piscataway, NJ. The final phase of the investigations was scheduled by the Commission following notification of preliminary determinations by Commerce that imports of lysine from China were subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 1671b(b)) and sold at LTFV within the meaning of 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission's investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the **Federal Register** on April 3, 2026 (91 FR 16967). The public hearing in connection with the investigations, originally scheduled for July 14, 2026, was cancelled.[4]

The Commission made these determinations pursuant to §§ 705(b) and 735(b) of the Act (19 U.S.C. 1671d(b) and 19 U.S.C. 1673d(b)). It completed and filed its determinations in these investigations on September 2, 2026. The views of the Commission are contained in USITC Publication 5783 (September 2026), entitled *L-Lysine from China: Investigation Nos. 701–TA–767 and 731–TA–1750 (Final).*

By order of the Commission.

Issued: September 2, 2026.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2026–18195 Filed 9–4–26; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–1761]**

### Importer of Controlled Substances Application: Fresenius Kabi USA, LLC

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Fresenius Kabi USA, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before October 8, 2026. Such persons may also file a written request for a hearing on the application on or before October 8, 2026.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on August 4, 2026, Fresenius Kabi USA, LLC, 3159 Staley Road, Grand Island, New York 14072–2028, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug Code | Schedule |
|---|---|---|
| Remifentanil ..... | 9739 | II |

The company plans to import the listed controlled substance(s) as bulk active pharmaceutical ingredient to manufacture Food and Drug Administration (FDA)-approved dosage forms. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA-approved or non-approved finished dosage forms for commercial sale.

**Justin Wood,**

*Deputy Assistant Administrator.*

[FR Doc. 2026–18201 Filed 9–4–26; 8:45 am]

**BILLING CODE P**

[1] The record is defined in § 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

[2] 91 FR 46399 and 91 FR 46406 (July 23, 2026).

[3] Commissioners Bart Thanhauser and David Foley Jr. did not participate in the vote.

[4] 91 FR 43667, July 16, 2026.